Tyra Biosciences (TYRA) Liabilities and Shareholders Equity (2020 - 2026)
Quarterly Liabilities and Shareholders Equity rose 19.96% to $412.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Mar 2026, down 10.95% year-over-year, with the annual reading at $282.6 million for FY2025, 22.27% down from the prior year.
Tyra Biosciences filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $412.0 million for Q1 2026.
- Liabilities and Shareholders Equity hit $412.0 million in Q1 2026 for Tyra Biosciences, up from $282.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $412.0 million in Q1 2026 and bottomed at $225.9 million in Q4 2023.
- Average Liabilities and Shareholders Equity over 5 years is $311.8 million, with a median of $299.0 million recorded in 2022.
- The largest annual shift saw Liabilities and Shareholders Equity soared 60.97% in 2024 before it dropped 22.27% in 2025.
- Tyra Biosciences' Liabilities and Shareholders Equity stood at $266.2 million in 2022, then dropped by 15.15% to $225.9 million in 2023, then soared by 60.97% to $363.6 million in 2024, then dropped by 22.27% to $282.6 million in 2025, then soared by 45.8% to $412.0 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Liabilities and Shareholders Equity are $412.0 million (Q1 2026), $282.6 million (Q4 2025), and $301.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 40.87 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 23.64 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 412.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 412.04 Mn |
| Dec 31, 2025 | 282.61 Mn |
| Sep 30, 2025 | 301.85 Mn |
| Jun 30, 2025 | 321.50 Mn |
| Mar 31, 2025 | 343.48 Mn |
| Dec 31, 2024 | 363.56 Mn |
| Sep 30, 2024 | 380.59 Mn |
| Jun 30, 2024 | 392.46 Mn |
| Mar 31, 2024 | 404.74 Mn |
| Dec 31, 2023 | 225.86 Mn |
| Sep 30, 2023 | 238.36 Mn |
| Jun 30, 2023 | 250.01 Mn |
| Mar 31, 2023 | 255.06 Mn |
| Dec 31, 2022 | 266.18 Mn |
| Sep 30, 2022 | 275.99 Mn |
| Jun 30, 2022 | 287.12 Mn |
| Mar 31, 2022 | 298.97 Mn |
| Dec 31, 2021 | 306.70 Mn |
| Sep 30, 2021 | 315.97 Mn |
| Dec 31, 2020 | 16.01 Mn |